Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,395 questions in 172 reviews · Gut
current versionsNo studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Stellate ganglion block vs sulphasalazine Treatment success as defined by the authors · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Stellate ganglion block vs sulphasalazine Pain frequency · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Stellate ganglion block vs sulphasalazine Pain intensity (measure on a 0‐3 four‐point scale) · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Stellate ganglion block vs sulphasalazine Withdrawals due to adverse events · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Low FODMAPs diet vs sham diet Pain intensity (0‐10cm visual analogue scale) · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | 1 study · 26 participants | Very low |
Low FODMAPs diet vs sham diet Withdrawal due to adverse events · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | RR 1.85 | 1 study · 52 participants | Very low |
Relaxation training vs wait‐list Treatment success as defined by the authors · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Relaxation training vs wait‐list Pain frequency (end of intervention, hours between pain episodes) · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | 1 study · 40 participants | Very low |
Relaxation training vs wait‐list Pain frequency (6 weeks after end of intervention, hours between pain episodes) · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | 1 study · 40 participants | Very low |
Relaxation training vs wait‐list Pain intensity (end of intervention, unidentified 0‐10 scale) · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | 1 study · 40 participants | Very low |
Relaxation training vs wait‐list Pain intensity (6 weeks after end of intervention, unidentified 0‐10 scale) · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | 1 study · 40 participants | Very low |
Oral 5‐ASA vs placebo Failure to induce complete global or clinical remission · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.86 [0.82, 0.89] | 11 studies · 2387 participants | High |
Oral 5‐ASA vs SASP Failure to induce endoscopic remission · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐ASA vs SASP Failure to adhere to medication regimen · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐ASA vs SASP Adverse events · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.48 [0.36, 0.63] | 12 studies · 909 participants | Moderate |
Oral 5‐ASA vs SASP Serious adverse events · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 1.36 [0.28, 6.52] | 2 studies · 107 participants | Low |
Oral 5‐ASA vs SASP Withdrawal due to adverse events · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.4 [0.24, 0.68] | 10 studies · 640 participants | Moderate |
Once daily dosing vs conventional dosing Failure to induce global or clinical remission · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.99 [0.93, 1.06] | 5 studies · 1761 participants | High |
Once daily dosing vs conventional dosing Failure to induce global or clinical improvement · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.74 [0.49, 1.1] | 3 studies · 564 participants | Moderate |
Once daily dosing vs conventional dosing Failure to induce endoscopic remission · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 1.02 [0.98, 1.07] | 1 study · 817 participants | High |
Once daily dosing vs conventional dosing Failure to adhere to medication regimen · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 1.36 [0.64, 2.86] | 2 studies · 358 participants | Low |
Once daily dosing vs conventional dosing Adverse events · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 1.02 [0.89, 1.18] | 4 studies · 1586 participants | Moderate |
Oral 5‐ASA vs placebo Failure to induce global or clinical improvement · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.68 [0.61, 0.75] | 14 studies · 2256 participants | Moderate |
Once daily dosing vs conventional dosing Serious adverse events · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 1.34 [0.68, 2.66] | 4 studies · 1586 participants | Low |
Once daily dosing vs conventional dosing Withdrawal due to adverse events · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.89 [0.54, 1.49] | 5 studies · 1757 participants | Low |
Oral 5‐ASA vs comparator 5‐ASA Failure to induce global or clinical remission · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.94 [0.86, 1.02] | 11 studies · 1968 participants | Moderate |
Oral 5‐ASA vs comparator 5‐ASA Failure to induce global or clinical improvement · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.89 [0.77, 1.01] | 8 studies · 1647 participants | Moderate |
Oral 5‐ASA vs comparator 5‐ASA Failure to induce endoscopic remission · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐ASA vs comparator 5‐ASA Failure to adhere to medication regimen · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐ASA vs comparator 5‐ASA Adverse events · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 1.01 [0.92, 1.12] | 9 studies · 1576 participants | Moderate |
Oral 5‐ASA vs comparator 5‐ASA Serious adverse events · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.59 [0.22, 1.56] | 4 studies · 677 participants | Low |
Oral 5‐ASA vs comparator 5‐ASA Withdrawal due to adverse events · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.94 [0.57, 1.54] | 9 studies · 1489 participants | Moderate |
Oral 5‐ASA vs placebo Failure to induce endoscopic remission · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.77 [0.67, 0.89] | 4 studies · 1154 participants | Moderate |
Oral 5‐ASA vs placebo Failure to adhere to medication regimen · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐ASA vs placebo Adverse events · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.95 [0.85, 1.07] | 8 studies · 1218 participants | High |
Oral 5‐ASA vs placebo Serious adverse events · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.53 [0.18, 1.56] | 4 studies · 746 participants | Low |
Oral 5‐ASA vs placebo Withdrawal due to adverse events · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.72 [0.54, 0.97] | 13 studies · 2372 participants | Moderate |
Oral 5‐ASA vs SASP Failure to induce global or clinical remission · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.9 [0.77, 1.04] | 8 studies · 526 participants | Moderate |
Oral 5‐ASA vs SASP Failure to induce global or clinical improvement · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | RR 0.88 [0.76, 1.01] | 14 studies · 1053 participants | High |
Oral 5‐aminosalicylic acid vs placebo Failure to maintain clinical or endoscopic remission · people with quiescent UC Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | RR 0.68 [0.61, 0.76] | 8 studies · 1555 participants | High |
Oral 5‐aminosalicylic acid vs sulfasalazine Serious adverse events · people with quiescent ulcerative colitis Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐aminosalicylic acid vs sulfasalazine Withdrawal due to adverse event · people with quiescent ulcerative colitis Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | RR 1.27 [0.87, 1.87] | 10 studies · 1585 participants | Moderate |
Oral 5‐aminosalicylic acid vs sulfasalazine Exclusion/withdrawal after entry · people with quiescent ulcerative colitis Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | RR 1.3 [1.04, 1.63] | 9 studies · 1497 participants | Moderate |
Once‐daily dosing vs conventional dosing Failure to maintain clinical or endoscopic remission · people with quiescent UC Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | RR 0.94 [0.88, 1.01] | 10 studies · 3910 participants | High |
Once‐daily dosing vs conventional dosing Failure to adhere to study medication regimen · people with quiescent UC Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | RR 1.18 [0.72, 1.93] | 9 studies · 2306 participants | Moderate |
Once‐daily dosing vs conventional dosing Adverse event · people with quiescent UC Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | RR 0.98 [0.92, 1.04] | 8 studies · 3497 participants | High |
Once‐daily dosing vs conventional dosing Serious adverse events · people with quiescent UC Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | RR 1.2 [0.77, 1.87] | 7 studies · 3196 participants | Moderate |
Once‐daily dosing vs conventional dosing Withdrawal due to adverse events · people with quiescent UC Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | RR 1.18 [0.74, 1.89] | 8 studies · 4340 participants | Very low |
Once‐daily dosing vs conventional dosing Exclusion/withdrawal after entry · people with quiescent UC Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | RR 0.99 [0.85, 1.15] | 7 studies · 3737 participants | High |
Oral 5‐aminosalicylic acid vs comparator 5‐aminosalicylic acid formulation Failure to maintain clinical or endoscopic remission · people with quiescent UC Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | RR 1.08 [0.91, 1.28] | 6 studies · 707 participants | Low |